Frequency: very often - more than 1/10, often - more than 1/100 and less than 1/10, infrequently - more than 1/1000 and less than 1/100, rarely - more than 1/10000 and less than 1/1000, very rarely - less than 1/10000, including individual cases.
From the nervous system: often - headache; infrequent - a violation of taste, including their loss (usually recovery occurs within a few weeks after cessation of treatment); very rarely - a decrease in appetite and weight loss, dizziness, paresthesia, hyperoscension.
From the skin:
very often - skin reactions (including rash, hives);
very rarely - Stevens-Johnson syndrome, toxic epidermal necrolysis, psoriasis-like rashes on the skin, exacerbation of existing psoriasis, alopecia. In case of progressing skin rash, treatment with terbinaphin should be discontinued.
From the hepatobiliary system: rarely - hepatobiliary dysfunction (mostly of a cholestatic nature), very rarely - severe hepatic insufficiency (some with fatal outcome or requiring liver transplantation).
In most cases, when hepatic insufficiency developed, patients had serious comorbid systemic diseases and the cause-and-effect relationship with terbinafine was doubtful.
From the digestive system: very often - a feeling of overflow of the stomach, a decrease in appetite, indigestion, nausea, mild abdominal pain, diarrhea.
From the musculoskeletal system:
very often - arthralgia, myalgia.
From the hematopoiesis: very rarely - neutropenia, agranulocytosis, pancytopenia. In the case of qualitative or quantitative changes in the blood constituents, consideration should be given to reducing the dose of the drug or, if necessary, to discontinue therapy.
From the immune system:
Very rarely - anaphylactoid reactions (including angioedema), cutaneous and systemic lupus erythematosus.
Other: very rarely - a feeling of fatigue.